• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Impact of the Severity of Liver Injury in COVID-19 Patients Admitted to an Intensive Care Unit During the SARS-CoV2 Pandemic Outbreak.在严重急性呼吸综合征冠状病毒2(SARS-CoV2)大流行期间,入住重症监护病房的2019冠状病毒病(COVID-19)患者肝损伤严重程度的影响
J Crit Care Med (Targu Mures). 2021 Aug 5;7(3):211-216. doi: 10.2478/jccm-2021-0021. eCollection 2021 Jul.
2
SARS-CoV-2 associated liver injury: a six-month follow-up analysis of liver function recovery.新型冠状病毒2型相关肝损伤:肝功能恢复的6个月随访分析
Med Pharm Rep. 2022 Oct;95(4):393-399. doi: 10.15386/mpr-2347. Epub 2022 Oct 27.
3
Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.在医院环境中评估羟氯喹化学预防 SARS-CoV2 感染在医护人员中的疗效和安全性的对照、双盲、随机试验:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):472. doi: 10.1186/s13063-020-04400-4.
4
Clinical and Epidemiological Features of SARS-CoV-2 Patients in SARI Ward of a Tertiary Care Centre in New Delhi.新德里一家三级医疗中心SARI病房中新冠病毒患者的临床和流行病学特征
J Assoc Physicians India. 2020 Jul;68(7):19-26.
5
Incidence, pattern and severity of abnormal liver blood tests among hospitalised patients with SARS-COV2 (COVID-19) in South Wales.南威尔士感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2,即新冠病毒)的住院患者肝脏血液检查异常的发生率、模式及严重程度
Frontline Gastroenterol. 2020 Aug 21;12(2):89-94. doi: 10.1136/flgastro-2020-101532. eCollection 2021.
6
Severe Coronavirus Disease Pneumonia in Pediatric Patients in a Referral Hospital.转诊医院中儿童患者的重症冠状病毒病肺炎
J Trop Pediatr. 2021 Jul 2;67(3). doi: 10.1093/tropej/fmab052.
7
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
8
An emergency strategy for intensive care unit during COVID-19 outbreak in Chongqing, China.中国重庆 COVID-19 疫情期间的重症监护病房应急策略。
Eur Rev Med Pharmacol Sci. 2020 Jul;24(14):7886-7888. doi: 10.26355/eurrev_202007_22294.
9
Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study.武汉儿童 2019 冠状病毒病重症患者的临床特征:单中心观察性研究。
World J Pediatr. 2020 Jun;16(3):251-259. doi: 10.1007/s12519-020-00354-4. Epub 2020 Mar 19.
10
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.意大利伦巴第地区 1591 名 ICU 收治的 SARS-CoV-2 感染患者的基线特征和结局。
JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394.

引用本文的文献

1
Long-Term Radiological Pulmonary Changes in Mechanically Ventilated Patients with Respiratory Failure due to SARS-CoV-2 Infection.新型冠状病毒肺炎(SARS-CoV-2)感染致呼吸衰竭机械通气患者的长期肺部影像学改变
Biomedicines. 2023 Sep 26;11(10):2637. doi: 10.3390/biomedicines11102637.
2
Prevention, diagnostic evaluation, management and prognostic implications of liver disease in critically ill patients with COVID-19.COVID-19危重症患者肝病的预防、诊断评估、管理及预后影响
World J Clin Cases. 2023 Jan 26;11(3):514-527. doi: 10.12998/wjcc.v11.i3.514.
3
SARS-CoV-2 associated liver injury: a six-month follow-up analysis of liver function recovery.新型冠状病毒2型相关肝损伤:肝功能恢复的6个月随访分析
Med Pharm Rep. 2022 Oct;95(4):393-399. doi: 10.15386/mpr-2347. Epub 2022 Oct 27.

本文引用的文献

1
Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis.新型冠状病毒肺炎患者的肝功能异常检查:相关性及潜在发病机制
Hepatology. 2020 Nov;72(5):1864-1872. doi: 10.1002/hep.31480. Epub 2020 Oct 20.
2
Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study.重症和非重症COVID-19患者的肝损伤:一项多中心、回顾性、观察性研究。
Front Med (Lausanne). 2020 Jun 23;7:347. doi: 10.3389/fmed.2020.00347. eCollection 2020.
3
Extrapulmonary manifestations of COVID-19.COVID-19 的肺外表现。
Nat Med. 2020 Jul;26(7):1017-1032. doi: 10.1038/s41591-020-0968-3. Epub 2020 Jul 10.
4
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.新型冠状病毒病 2019(COVID-19)的病理生理学、传播、诊断和治疗:综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
5
Liver injury in COVID-19: The current evidence.新型冠状病毒肺炎相关肝损伤:当前证据。
United European Gastroenterol J. 2020 Jun;8(5):509-519. doi: 10.1177/2050640620924157.
6
The liver in times of COVID-19: What hepatologists should know.COVID-19 时期的肝脏:肝病学家应该了解的知识。
Ann Hepatol. 2020 Jul-Aug;19(4):353-358. doi: 10.1016/j.aohep.2020.05.001. Epub 2020 May 18.
7
COVID-19 Related Liver Injury: Call for International Consensus.
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2848-2851. doi: 10.1016/j.cgh.2020.05.013. Epub 2020 May 17.
8
We Know Liver Biochemistries Are Elevated in COVID-19, But Should We Be Concerned?我们知道新冠病毒肺炎患者的肝脏生化指标会升高,但我们应该担心吗?
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2384-2385. doi: 10.1016/j.cgh.2020.05.018. Epub 2020 May 16.
9
Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies.肝损伤与2019年冠状病毒病(COVID-19)重症感染相关:一项回顾性研究的系统评价和荟萃分析
Hepatol Res. 2020 Aug;50(8):924-935. doi: 10.1111/hepr.13510. Epub 2020 Jun 25.
10
Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications.COVID-19 患者的肝脏受累:病理学、发病机制和临床意义。
J Med Virol. 2020 Sep;92(9):1491-1494. doi: 10.1002/jmv.25973. Epub 2020 May 13.

在严重急性呼吸综合征冠状病毒2(SARS-CoV2)大流行期间,入住重症监护病房的2019冠状病毒病(COVID-19)患者肝损伤严重程度的影响

Impact of the Severity of Liver Injury in COVID-19 Patients Admitted to an Intensive Care Unit During the SARS-CoV2 Pandemic Outbreak.

作者信息

Roman Adina, Moldovan Septimiu, Santini Ario, Stoian Mircea, Dobru Daniela

机构信息

Mures County Hospital, Targu Mures, Romania.

George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania.

出版信息

J Crit Care Med (Targu Mures). 2021 Aug 5;7(3):211-216. doi: 10.2478/jccm-2021-0021. eCollection 2021 Jul.

DOI:10.2478/jccm-2021-0021
PMID:34722924
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8519387/
Abstract

INTRODUCTION

The World Health Organization (WHO) identified a novel coronavirus, originating in Wuhan, China, in December 2019, as a pneumonia causing pathogen. Epidemiological data in Romania show more than 450.000 confirmed patients, with a constant number of approximately 10% admission in intensive care unit.

METHOD

A retrospective, observational study was conducted from 1st March to 30th October 2020, comprising 657 patients, confirmed as having COVID-19, and who had been admitted to the intensive care unit of the Mures County Clinical Hospital, Tîrgu Mures, Romania, which had been designated as a support hospital during the pandemic. Patients who presented at admission or developed abnormal liver function tests in the first seven days of admission, were included in the study; patients with pre-existing liver disease, were excluded.

RESULTS

The mean (SD) age of patients included in the study was 59.41 (14.66) years with a male: female ratio of 1.51:1. Survivor status, defined as patients discharged from the intensive care unit, was significantly associated with parameters such as age, leukocyte count, albumin level, glycaemia level (p<0.05 for all parameters.).

CONCLUSIONS

Liver injury expressed through liver function tests cannot solely constitute a prognostic factor for COVID-19 patients, but its presence in critically ill patients should be further investigated and included in future guideline protocols.

摘要

引言

世界卫生组织(WHO)于2019年12月确定起源于中国武汉的一种新型冠状病毒是一种导致肺炎的病原体。罗马尼亚的流行病学数据显示,确诊患者超过45万,重症监护病房的收治人数持续保持在约10%。

方法

于2020年3月1日至10月30日进行了一项回顾性观察研究,纳入657例确诊感染新冠病毒且已入住罗马尼亚特尔古穆列什市穆列什县临床医院重症监护病房的患者,该医院在疫情期间被指定为支援医院。入院时出现或入院后前七天内肝功能检查异常的患者被纳入研究;排除既往有肝病的患者。

结果

纳入研究的患者平均(标准差)年龄为59.41(14.66)岁,男女比例为1.51:1。存活状态定义为从重症监护病房出院的患者,与年龄、白细胞计数、白蛋白水平、血糖水平等参数显著相关(所有参数p<0.05)。

结论

通过肝功能检查表现出的肝损伤不能单独构成新冠病毒感染患者的预后因素,但在重症患者中其存在情况应进一步研究并纳入未来的指南方案。